Genmab A/S (CPH:GMAB)
Denmark · Delayed Price · Currency is DKK | Market Cap | 126.77B |
| Revenue (ttm) | 24.48B |
| Net Income (ttm) | 10.08B |
| Shares Out | 61.60M |
| EPS (ttm) | 159.78 |
| PE Ratio | 12.88 |
| Forward PE | 18.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 253,673 |
| Average Volume | 115,848 |
| Open | 2,022.00 |
| Previous Close | 2,004.00 |
| Day's Range | 2,022.00 - 2,081.00 |
| 52-Week Range | 1,157.00 - 2,153.00 |
| Beta | 0.79 |
| RSI | 57.65 |
| Earnings Date | Feb 5, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]
Financial Performance
In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.
Financial numbers in USD Financial StatementsNews
Genmab Meets Conditions For $97/shr Merus Tender Offer
(RTTNews) - Genmab A/S (GMAB), a Danish biotechnology company's subsidiary, Genmab Holding II B.V., announced on Friday that the conditions to its tender offer to acquire all Merus N.V. (MRUS) shares ...
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “O...
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to Genmab's EBITDA by e...
Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions - Slideshow
Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2025 – Genmab A/S (Nasdaq: GMAB) will hold its 2025 R&D Update and ASH Data ...
Genmab (GMAB) Highlights Promising Results from EPCORE CLL-1 Trial
Genmab (GMAB) Highlights Promising Results from EPCORE CLL-1 Trial
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the efficacy...
Genmab : Phase 3 Trial Shows EPKINLY + R2 Cuts Progression Risk By 79% And Achieves 95% ORR In FL
(RTTNews) - Genmab A/S (GMAB) announced primary results from the pivotal Phase 3 EPCORE FL-1 study, evaluating fixed-duration EPKINLY (epcoritamab-bysp) in combination with rituximab and lenalidomide ...
Genmab (GMAB) Reports Positive Phase 3 Study Results for EPKINLY Therapy
Genmab (GMAB) Reports Positive Phase 3 Study Results for EPKINLY Therapy
Genmab (GMAB) Reports Promising Clinical Trial Outcomes for Epcoritamab
Genmab (GMAB) Reports Promising Clinical Trial Outcomes for Epcoritamab
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
Media Release COPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R 2) resulted in statistically significant and c...
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced primary data from the pivotal Phase 3 EPCORE® FL-1 study evaluating fixed duration EPKINLY® (epcoritamab-bysp) in combin...
Genmab Reports Promising Clinical Trial Results For Fixed-Duration Epcoritamab In Lymphoma
(RTTNews) - Genmab A/S (GMAB) announced updated findings from multiple ongoing clinical trials evaluating epcoritamab-bysp, a subcutaneously administered, T-cell engaging antibody.
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Media Release COPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE ® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in ...
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated results from two ongoing clinical trials evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engagi...
Genmab A/S at Citi Global Healthcare Conference Transcript
Genmab A/S at Citi Global Healthcare Conference Transcript
Genmab A/S (GMAB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter
Genmab stock, Thursday's IBD Stock Of The Day, is just below an early entry in a cup case after announcing an $8 billion deal to buy Merus.
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes
Media Release COPENHAGEN, Denmark; December 3, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have closed their...
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Company Announcement COPENHAGEN, Denmark; December 1, 2025 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, ...
Genmab (GMAB) Q3 2025 Earnings Call Transcript
Genmab (GMAB) Q3 2025 Earnings Call Transcript
Artisan International Small-Mid Fund Q3 2025 Performance Review
Security selection in industrials and a notable overweight to the software industry within information technology were the key detractors from relative returns. Health care is among the three weakest ...
Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami
Media Release COPENHAGEN, Denmark; November 24, 2025 Genmab A/S (Nasdaq: GMAB) announced today that its C hief F inancial O fficer Anthony Pagano will participate in a fireside chat at the Citi Globa...
Genmab A/S (GMAB) Presents at Jefferies London Healthcare Conference 2025 Transcript
Genmab A/S (GMAB) Jefferies London Healthcare Conference 2025 November 19, 2025 7:00 AM EST Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - Executive VP & CFO Con...